FDAnews Device Daily Bulletin
Medical Devices / Submissions and Approvals

German Devicemaker Gets CE-IVD Mark for Lung Cancer Assay

Dec. 22, 2017
A A

Epigenomics, a Germany-based molecular diagnostics company, received the CE-IVD mark for its blood-based lung cancer test Epi proLung.

The device includes the company’s proprietary DNA methylation biomarkers.

The European Commission provided funding for the development of the assay, the company said.

View today's stories